Senior Director, Global Commercial Product Strategy, Urothelial and Gynaecological Cancer (UC -GYN)
GILEAD SCIENCES
11.2022 - Current
Cross-functional team (CFT) lead: successfully led the commercial team (CT) for the development of the Indication Strategic Plan (ISP), and the global CFT launch readiness at 18 and 12 months prior to launch, achieving VP approval and affiliate appreciation
Spearheaded a comprehensive global Key Opinion Leader (KOL) strategy, profiled 150 and engaged > 45, created a global council
Direct report: Managed a global director as omnichannel lead (via talent marketplace, 50% time): successfully deployed a pre-launch campaign that enhanced visibility and engagement of Gilead in UC and led digital strategy with omnichannel proposal for UC
Led Disease Area Strategy for Gynaecological Cancers (cervical, ovarian and endometrial) (GYN-DAS): PC approved action plan
Director, Global Commercial Product Strategy, Breast cancer (BC)- Trodelvy first global launch
GILEAD SCIENCES
02.2021 - 11.2022
Led global campaign deliverables and omnichannel strategy with high affiliate secondment and alignment
KOL strategy lead: delivered internal and external global launch meetings
VP recognized with >15 KOLs; >250 attendees and replicated by over 7 affiliates involving EU5 and mid-size markets
TNBC launch readiness, competitive differentiation and commercial assessment lead: localized by EU5 markets
Global Launch Excellence (GLE) Director- Filgotinib first global launch
GILEAD SCIENCES
06.2020 - 02.2021
Oversaw launch readiness for ACE mid-size affiliates developing business cases, LE, POA, KPIs and best practice sharing
Marketing lead, Senior Brand Manager, Cancer Immunotherapy - TECENTRIQ launch, Lung Cancer. First ACE launch.
ROCHE PRODUCTS LTD
06.2018 - 06.2020
Developed launch campaign, strategy for all-comers, launch meeting and sales training
Responsible for price and reimbursement (P&R) applications for new launches/indications (value dossier, pricing strategy, economic and budget impact models for heath technology assessment submissions), obtaining P&R timely and within price corridor
Developed CVM portfolio lifecycle strategy in collaboration with regulatory affairs aiming to minimize risk of price decrease, achieving a -1,7% adjustment on a CVM product with high risk of - 30% price cut
Conducted market access plan and gap analysis for early phase products (from ph II) to inform Region Europe plans
In-market Access: Developed Access Brand Plans (BP) and developed health economic (HE) product-specific tools supported by authorship of HE&OR publications (Rubio-Terres C
Et al, Rev Esp Quimioter 2012; Sicras-Mainar et al, Med Clin (Ba(rc), 2013; held poster presentations at AES and ISPOR
Access lead of CVM 'ITHACA' patient support programme